At one point, BMS said the facility would house 400 people. That was before Chairman and CEO Chris Boerner replaced Giovanni ...

For decades, researchers have worked to create drugs that teach the immune system to kill cancer cells the way traditional vaccines attack viruses. But while cancer vaccines have shown flashes of ...

The FDA advances in multiple cancer types, and researchers assess potential impacts of funding freezes on cancer research.

Opdivo continues to maintain momentum on consistent ... It expects the remaining $400 million to be realized in 2025. Concurrent with the fourth-quarter results, BMY announced an expansion to ...

Some of those sales are cannibalising sales of Opdivo monotherapy and the combination ... with sales around $400 million ahead of expectations. Caforio said there was also significant progress ...

Opdivo/Yervoy was cleared for BRAF V600-positive ... Over the same period, Cotellic sales have shrunk from around $400 million to a little over $50m last year as immunotherapy displaced targeted ...

(Reuters) Citing $400 million in federal funding at risk ... Neoadjuvant therapy that included nivolumab (Opdivo) significantly improved overall survival in resectable non-small cell lung cancer ...